Selegiline Transdermal System for the Treatment of Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Trial
Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.
From the Department of Psychiatry, University of Colorado School of Medicine, Denver; Research Training Associates (RTA) Colorado, Lakewood; and Feiger Health Research Center, Wheat Ridge, Colo. (Dr. Feiger); the Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia (Dr. Rickels); the Child and Adolescent Psychiatric Division, New York State Psychiatric Institute/Columbia University, New York (Dr. Rynn); the Pacific Clinical Research Medical Group, Upland, Calif. (Dr. Zimbroff); and Worldwide Drug Development, Burlington, Vt. (Dr. Robinson).
J Clin Psychiatry. 2006 Sep;67(9):1354-1361.


OBJECTIVE: This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD). METHOD: Patients meeting DSM-IV criteria for MDD (N = 265) were randomly assigned to blinded treatment with STS or a matching placebo patch for 8 weeks. Patients failing to meet or maintain protocol-defined therapeutic response criteria at predetermined time points had their STS (or placebo) dose increased. Assessments were conducted at weeks 1, 2, 3, 5, 6, and 8. Patients were not required to follow a tyramine-restricted diet. The study ran from September 2001 through August 2002. RESULTS: Selegiline transdermal system treatment resulted in significantly greater improvement (p < / = .05) compared with placebo treatment on the 3 depression rating scales: the 28-item Hamilton Rating Scale for Depression (HAM-D(28)) (primary outcome measure), the Montgomery-Asberg Depression Rating Scale, and the Inventory for Depressive Symptomatology-Self Rated. The treatment effect measured by the HAM-D(28) was modest, primarily due to insomnia side effects. The antidepressant efficacy of STS was substantiated further by the significantly greater improvement in core depression symptoms (HAM-D Bech-6 subscale). The side effects of highest incidence were applicationsite reactions and insomnia. There were no safety concerns based on routine clinical laboratory and electrocardiogram monitoring, and there were no occurrences of hypertensive crisis. CONCLUSION: Results of this double-blind, placebo-controlled, dose titration trial provide evidence of short-term efficacy, safety, and tolerability of STS in the dose range of 6 mg/24 hours to 12 mg/24 hours for treatment of MDD. Selegi-line transdermal system has an improved margin of safety compared with oral monoamine oxidase inhibitors and represents a useful addition to the existing array of antidepressants.
Transdermal selegiline
Selegiline and nitric oxide
Selegiline and life-expectancy
Selegiline for longer-lived flies
'New generation' MAOIs: EMSAM
Selegiline for cocaine dependence
Selegiline patch (Emsam) as an antidepressant
Transdermal selegiline without dietary restrictions
Feb 2006: EMSAM (selegiline transdermal system) licensed by FDA
Transdermal selegiline / l-deprenyl (EMSAM) to combat major depression

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family